CLENPIQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLENPIQ (CLENPIQ).
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
| Metabolism | Bisacodyl (picosulfate) is hydrolyzed by colonic bacteria to its active metabolite BHPM; magnesium citrate acts locally. |
| Excretion | Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%) |
| Half-life | Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component |
| Protein binding | Sodium picosulfate: <5% bound to plasma proteins |
| Volume of Distribution | Sodium picosulfate: Vd ~0.2 L/kg (confined mainly to extracellular fluid, low tissue penetration) |
| Bioavailability | Oral (sodium picosulfate): low systemic bioavailability (<10%) due to extensive first-pass activation in colon; magnesium citrate is a locally active osmotic agent with negligible systemic absorption |
| Onset of Action | Oral: First bowel movement typically within 1–2 hours; full effect within 4 hours |
| Duration of Action | Bowel cleansing effect persists for 4–6 hours after last dose (until colon is cleared); residual effects may last up to 12 hours |
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated if eGFR < 30 mL/min/1.73 m². For eGFR 30-59 mL/min/m²: reduce total prucalopride dose to 5 mg (i.e., single administration only). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild to moderate impairment (Child-Pugh A or B). |
| Pediatric use | Not approved for use in pediatric patients (<18 years). Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required solely based on age. Consider renal function (eGFR) and overall frailty; use conservative dosing in elderly with renal impairment (see renal_adjustment). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLENPIQ (CLENPIQ).
| Breastfeeding | Excretion in human milk unknown. M/P ratio not available. Because many drugs are excreted in human milk, caution should be exercised when CLENPIQ is administered to a nursing woman. Consider temporary discontinuation of breastfeeding during the 24-hour period after CLENPIQ administration. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to pregnant rats during organogenesis at doses up to 1.2 times the human dose (based on body surface area) did not produce fetal harm. However, because animal studies are not always predictive of human response, CLENPIQ should be used during pregnancy only if clearly needed. During the first trimester, consider alternative bowel preparation to avoid any theoretical risk. In second and third trimesters, use only if potential benefit justifies potential risk to fetus. |
■ FDA Black Box Warning
WARNING: RISK OF SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. CLENPIQ can cause significant fluid and electrolyte shifts, which may lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. Monitor and correct electrolytes before use in patients at risk.
| Serious Effects |
["Gastrointestinal obstruction","Gastric retention","Bowel perforation","Toxic colitis","Toxic megacolon","Ileus","Hypersensitivity to any component","Severe renal impairment (eGFR <30 mL/min/1.73m²)"]
| Precautions | ["Risk of fluid and electrolyte abnormalities","Cardiac arrhythmias due to electrolyte imbalance","Seizures associated with electrolyte abnormalities","Renal impairment","Mucosal ulceration","Use with caution in patients with impaired gag reflex, reflux, or aspiration risk","Colonic mucosal aphthous ulcerations"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal fluid and electrolyte balance (serum sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate) before and after administration. Monitor for signs of dehydration, arrhythmias (ECG), and seizures. No specific fetal monitoring required, but assess fetal well-being if maternal status is compromised. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of fertility was observed in rats at doses up to 1.2 times the human dose. |